The Leukemia & Lymphoma Society's (LLS's) academic grants support and encourage basic and translational leukemia, lymphoma and myeloma research.
LLS investigators are outstanding scientists at the forefront of leukemia, lymphoma and myeloma research at centers throughout the world. We award academic grants for studies that range from basic blood cancer research to research that uses the latest tools of genomics.
And we don't stop there. We're also dedicated to funding blood cancer research to help improve the quality of life for patients and their families with our projects studying long-term and late effects.
Visit LLS's Research Portal to apply for funding from LLS.
Learn more
A resource for those with currently active LLS grants or awards.
Learn more
Highlighting brand new publications and advances produced by LLS-funded blood cancer research.
View
See a list of the investigators whose projects were awarded funding in 2019.
View List
Due to the COVID-19 pandemic impact on LLS fundraising activities, the Career Development Program will not be open for submission of new applications in 2020. The Leukemia & Lymphoma Society (LLS) offers career development awards to postdoctoral fellows and instructors, as well as early-career independent investigators, engaging in basic, clinical, or translational research to help unders...
Due to the COVID-19 pandemic impact on LLS fundraising activities, the Translational Research Program will not be open for submission of new applications in 2020. The Translational Research Program (TRP) puts you on the bench-to-bedside fast track when it comes to finding better treatment and cures for leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society funds new and innovative research...
Due to the COVID-19 pandemic impact on LLS fundraising activities, the Specialized Center of Research Program will not be open for submission of new applications in 2020. LLS’s Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and e...
The Blood Cancer Discoveries Grant Program will not open for new applications this year. The Leukemia & Lymphoma Society (LLS), the Mark Foundation for Cancer Research (MFCR), and The Paul G. Allen Frontiers Group (PAFG) are proud to announce the Blood Cancer Discoveries Grant Program (BCDG), a new grant program designed to encourage basic research, technological innovation, and informatics pipeline de...
The IMPACT program will not open for new applications this year. The Leukemia & Lymphoma Society's Influential Medicine Providing Access to Clinical Trials ("IMPACT") program is intended to expand access to high-quality clinical trials to patients served by community health settings, particularly rural, minority, and/or economically disadvantaged blood cancer patients. As ...
The Screen to Lead Program will not open for new applications this year. The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators t...
The RTFCCR/LLS Patient-Focused Prevention Program will not open for new applications this year. The Rising Tide Foundation for Clinical Cancer Research and the Leukemia & Lymphoma Society partner in an international competitive grant to advance breakthroughs in prevention for blood cancers. The grant is focused on addressing four critical topics and is endowed with a total of USD $3 million.&n...
RTFCCR/LLS Patient-Focused Immunotherapy Research Grant for Blood Cancer will not open for new applications this year. The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a private foundation in Switzerland, is focused on funding promising, innovative translational studies and clinical trials that hold the promise of delivering hopeful, encouraging and immediate options for cancer patient...